Press Releases

Date Title
July 16, 2014
Strides Arcolab makes strategic investment in Oncobiologics
July 16, 2014:  Cranbury, NJ  Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics, Inc, a privately held New Jersey biopharmaceutical firm developing a pipeline of biosimilars and next generation biotherapeutics.
June 26, 2014
Liomont and Oncobiologics partner to launch Biosimilars in Mexico
Cranbury, NJ – June 26, 2014 — Oncobiologics, Inc. and Laboratorios Liomont S.A. de C.V. announced today a strategic partnership for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market.  The scope of the agreement includes exclusive
June 12, 2014
Oncobiologics launches Phase I Clinical Trial for ONS-3010 Biosimilar version of Humira®
Cranbury, NJ – June 12, 2014 — Oncobiologics, Inc. announced today that it has received approval to initiate a Phase I clinical trial in Europe for its first biosimilar molecule, ONS-3010, a highly biosimilar version of the marketed drug, Humira®. After reviewing Oncobiologics’ Clinical Trial
June 2, 2014
Ipca and Oncobiologics Create Strategic Biosimilars Partnership
Mumbai, India and New Jersey, USA – June 2, 2014 — Ipca Laboratories Ltd., India (Ipca) and Oncobiologics, Inc., USA (Oncobiologics) announced today the creation of a two-part alliance for the development, manufacture and commercialization of biosimilar monoclonal antibody products.  Under the
May 23, 2014
Oncobiologics CEO named finalist in EY Entrepreneur Of The Year 2014 New Jersey program
Oncobiologics Founder and CEO Pankaj Mohan, Ph.D. was named a finalist in the EY Entrepreneur Of The Year 2014 for New Jersey program. This award recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment
Displaying 191 - 195 of 195